Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19

3-Aug-2020 9:00 AM EDT, by Neutrolis

- Novel Chromatinase™ platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19

- Investigational biologic aims to treat hyperinflammation and thrombosis in COVID-19 patients, including those with Acute Respiratory Distress Syndrome (ARDS)

 

- Neutrolis awarded competitive grant from the National Institutes of Health (NIH)

- Recent study published in The Lancet EBioMedicine found NETs in COVID-19 patients

 

Newswise — CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.

"We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. "Our lead compound, NTR-441, and other molecules from our Chromatinase™ platform are the only drugs currently in development that could systemically remove NETs from the body. Thanks in part to competitive funding from the National Institutes of Health (R43HL150944), we will test whether NTR-441 is effective in ARDS, the most lethal manifestation of COVID-19."

Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19.

"We just published a study of patients who succumbed to COVID-19 in EBioMedicine published by The Lancet. Surprisingly, we found NETs congesting blood vessels in the lungs of all patients. Clearing these NETs with NTR-441 to restore blood flow may help patients survive COVID-19," said Martin Herrmann, M.D., Ph.D., Professor of Experimental Medicine from the University Hospital Erlangen in Germany, who has studied NETs extensively for the past 15 years.

"NETs may also induce microthrombosis in many organs causing organ failure or strokes. All of these thrombotic events are highly prevalent in COVID-19 patients," said Denisa Wagner, Ph.D., Edwin Cohn Professor of Pediatrics at Boston Children's Hospital (BCH), Harvard Medical School, which licensed Neutrolis some of the intellectual property that underpins the Chromatinase™ platform.

"NETs are a fundamental but unaddressed culprit in a wide array of human diseases. As a critical care specialist and pulmonologist, I think that an efficient therapy against NETs will be important for patients with COVID-19 and other causes of ARDS," said Mark Looney, M.D., Professor of Medicine at University of California, San Francisco and an expert in ARDS.  "If proven safe and effective, NTR-441 could benefit a wide array of patients long after the coronavirus pandemic has ended."

About NTR-441

  • NTR-441—an engineered analog of the natural NET-destroying enzyme DNASE1L3—is the world's first investigational drug that can be systemically delivered to accurately target NETs.
  • In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs.
  • NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.

About NETs

  • NETs are sticky, web-like structures made of chromatin—DNA studded with structural proteins—and expelled by suicidal neutrophils.
  • NETs block air sacs and blood vessels in the lungs, trigger hyperinflammation and blood clotting (thrombosis), potentially causing irreversible end-organ damage and death.

About Neutrolis 
Neutrolis is a biotechnology company developing first-in-class therapies that target neutrophils and their pathogenic products, including NETs. Neutrolis' proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form NETs. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis and other NET-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company is privately held and has been supported to date by First Rice Capital and Prefix Capital, as well as individual investors and funding from the National Institutes of Health. It was founded by Drs. Toby Fox and Abdul Hakkim, two of the earliest and most cited leaders in the NETs field. 




Filters close

Showing results

110 of 3327
Newswise: How to Keep Children Safe from COVID-19 this Fall
Released: 18-Sep-2020 4:15 PM EDT
How to Keep Children Safe from COVID-19 this Fall
Rush University Medical Center

With the new school year started and autumn approaching, Colleen Nash, MD, MPH, Rush University Medical Center, pediatric infectious disease specialist, answers questions parents may have about keeping children safe from COVID, social distancing in the classroom and celebrating Halloween.

Released: 18-Sep-2020 4:05 PM EDT
Claims circulating on social media stating that the common cold or flu can be mistaken for COVID-19 are misleading
Newswise

The claims rely on the faulty assumption that there is no method to distinguish COVID-19 from the common cold and the flu.

Released: 18-Sep-2020 3:35 PM EDT
After developing CRISPR test, UConn researchers validate clinical feasibility for COVID-19 testing
University of Connecticut

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

Newswise:Video Embedded blowin-in-the-wind
VIDEO
Released: 18-Sep-2020 3:10 PM EDT
Blowin' in the wind
University of Utah

University of Utah chemical engineers have conducted an air flow study of the venue that the Utah Symphony performs in to determine the best ways to mitigate the spread of COVID-19 through the emissions of wind instrument players.

Newswise: holman1_toned-1-768x512.jpg
Released: 18-Sep-2020 2:50 PM EDT
Study links rising stress, depression in U.S. to pandemic-related losses, media consumption
University of California, Irvine

Irvine, Calif., Sept. 18, 2020 – Experiencing multiple stressors triggered by the COVID-19 pandemic – such as unemployment – and COVID-19-related media consumption are directly linked to rising acute stress and depressive symptoms across the U.S., according to a groundbreaking University of California, Irvine study. The report appears in Science Advances, published by the American Association for the Advancement of Science.

Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.


Showing results

110 of 3327

close
1.45525